Live Webinar: The Ultimate Cleaning Validation Audit Readiness Blueprint. Register Now
Live Webinar: The Ultimate Cleaning Validation Audit Readiness Blueprint. Register Now
Experience Leucine AI .
Powered Pharma Operations

Transform Your Pharma Operations with AI-Powered Intelligence. Experience how Leucine's integrated platform brings together manufacturing, quality, and laboratory operations in one digital ecosystem. Schedule a personalized demo to see how our AI solutions can optimize your processes, ensure compliance, and drive operational excellence.

See How AI Transforms Your Shop Floor Operations.
Experience firsthand how Leucine's 10x MES digitalizes batch records, streamlines production, and provides real-time monitoring of your manufacturing operations. Schedule a personalized demo to discover how our AI-powered platform can enhance your productivity while maintaining compliance.

Experience AI-Driven Quality Management in Action.
See how Leucine's 10x QMS automates compliance workflows, streamlines change control, and ensures regulatory adherence. Schedule a demo to learn how our AI-powered platform can help you manage quality processes more efficiently while reducing compliance risks.

Discover Smart Laboratory Operations Management.
Watch how Leucine's 10x LES orchestrates your lab operations, automates documentation, and ensures data integrity. Schedule a demo to see how our AI-powered platform can accelerate your testing processes while maintaining audit-readiness.

Optimize your manufacturing processes with paperless operations
Strengthen quality management and regulatory compliance
Accelerate laboratory operations and testing workflows

Connect with a Leucine Expert

Schedule a 30-Minute Product Demo with Expert Q&A

Sub System /
Process Validation
Process Validation
View Detailed Analysis

Analytics Overview

88
Form 483s Issued
15
483s converted to WL
112
Total Observation
Form 483s Issued
+74 from last period

Analytics Overview

Form 483 Conversion Rate by Year
Form 483s Issued (Yearly)

Recent Form 483s & Warning Letters

View all 483’s
Issue Date
Facility Name
Product Type
Form 483
Converted
Warning Letter
18 Jul 2025
Dr. Reddy's Laboratories Limited , FTO-11
Drugs
18 Jul 2025
Right Value Drug Stores LLC
Drugs
27 Jun 2025
BSO, LLC
Drugs
19 Jun 2025
NATCO Pharma Limited
Drugs
23 May 2025
Stokes Healthcare Inc. dba Epicur Pharma
Drugs

Top Investigators

Investigator Name
Form 483 Count
Warning Letter Count
Justin A Boyd
14
7
Anastasia M Shields
10
6
Demario L Walls
5
0
Arsen Karapetyan
5
1
Joseph A Piechocki
5
0
TITLE/ COMPANY Issue Date Status Details
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic process.
Dr. Reddy's Laboratories Limited , FTO-11
18 Jul 2025 Normal Justification: Process Validation is identified due to failure in validating aseptic processes critical for sterile production integrity.
Excerpt: Poor visualization was seen due to inadequate generation of smoke to ensure that (b) (4) sweeping unidirectional airflow is present.
View Details
Written procedures are not established that describe the in-process controls, tests and examinations to be conducted on appropriate samples of in-process materials of each batch.
Right Value Drug Stores LLC
18 Jul 2025 Normal Justification: The lack of validation studies is critical to ensuring that the manufacturing process reliably produces quality products.
Excerpt: There are no documented validation studies demonstrating that your hormonal pellet manufacturing process consistently produces pellets meeting specifications.
View Details
There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed.
Dr. Reddy's Laboratories Limited , FTO-11
18 Jul 2025 Normal Justification: OOS results were recurring, indicating poorly validated processes unable to ensure consistency.
Excerpt: OOS results... were recurring in nature due to system failures.
View Details
Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design to facilitate operations for its intended use.
BSO, LLC
27 Jun 2025 Normal Justification: Process Validation is affected due to absence of validated equivalency between qualification and actual processing conditions.
Excerpt: No study was provided to demonstrate equivalency between the qualification materials and actual product formulation.
View Details
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the sterilization process.
BSO, LLC
27 Jun 2025 Normal Justification: Validation is a key part of any process to ensure consistency and reliability. Failure to validate fully exposes the product to contamination risks.
Excerpt: Your firm failed to establish and document adequate validation of the (b) (4) sterilization process used for Estradiol Pellets.
View Details

Prepare Better for FDA Audits with FDA Tracker

Get Real-time Insights: FDA 483s & Warning letters.
Uncover Trends: FDA Investigator profiles & Observations.
Stay Compliant: Manage risks proactively.

Process Validation

Explore essential insights on batch release processes to enhance compliance and quality. Dive into our article for practical guidance and best practices.

Written By
Vivek Gera
Reading Time
8
Minutes

Process Validation

Overview

88
Form 483s Issued
15
483s converted to WL
112
Total Observation
Form 483s Issued
+74 from last period

Recent Form 483s & Warning Letters

Issue Date
Facility Name
Product Type
Form 483
Converted
Warning Letter
18 Jul 2025
Dr. Reddy's Laboratories Limited , FTO-11
Drugs
18 Jul 2025
Right Value Drug Stores LLC
Drugs
27 Jun 2025
BSO, LLC
Drugs
19 Jun 2025
NATCO Pharma Limited
Drugs
23 May 2025
Stokes Healthcare Inc. dba Epicur Pharma
Drugs

Top FDA Investigators

Investigator Name
Form 483 Count
Warning Letter Count
Justin A Boyd
14
7
Anastasia M Shields
10
6
Demario L Walls
5
0
Arsen Karapetyan
5
1
Joseph A Piechocki
5
0

Key Observations

TITLE/ COMPANY Issue Date Status Details
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic process.
Dr. Reddy's Laboratories Limited , FTO-11
18 Jul 2025 Normal Justification: Process Validation is identified due to failure in validating aseptic processes critical for sterile production integrity.
Excerpt: Poor visualization was seen due to inadequate generation of smoke to ensure that (b) (4) sweeping unidirectional airflow is present.
View Details
Written procedures are not established that describe the in-process controls, tests and examinations to be conducted on appropriate samples of in-process materials of each batch.
Right Value Drug Stores LLC
18 Jul 2025 Normal Justification: The lack of validation studies is critical to ensuring that the manufacturing process reliably produces quality products.
Excerpt: There are no documented validation studies demonstrating that your hormonal pellet manufacturing process consistently produces pellets meeting specifications.
View Details
There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed.
Dr. Reddy's Laboratories Limited , FTO-11
18 Jul 2025 Normal Justification: OOS results were recurring, indicating poorly validated processes unable to ensure consistency.
Excerpt: OOS results... were recurring in nature due to system failures.
View Details
Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design to facilitate operations for its intended use.
BSO, LLC
27 Jun 2025 Normal Justification: Process Validation is affected due to absence of validated equivalency between qualification and actual processing conditions.
Excerpt: No study was provided to demonstrate equivalency between the qualification materials and actual product formulation.
View Details
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the sterilization process.
BSO, LLC
27 Jun 2025 Normal Justification: Validation is a key part of any process to ensure consistency and reliability. Failure to validate fully exposes the product to contamination risks.
Excerpt: Your firm failed to establish and document adequate validation of the (b) (4) sterilization process used for Estradiol Pellets.
View Details

Frequently Asked Questions

Heading 1

Heading 2

Heading 3

Heading 4

Heading 5
Heading 6

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.

Block quote

Ordered list

  1. Item 1
  2. Item 2
  3. Item 3

Unordered list

  • Item A
  • Item B
  • Item C

Text link

Bold text

Emphasis

Superscript

Subscript

Experience Leucine AI Powered pharma manufacturing
300+ pharma facilities worldwide use Leucine to stay compliant. Talk to one of our expert consultants at Leucine to learn how.
Related Resources

View and learn more about FDA Inspections
with our comprehensive list of resources